omniture
杭州阿诺生物医药科技有限公司 Adlai Nortye

Latest News

Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs

NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 14, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai...

2022-03-15 02:00 1862

Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2)in Frontiers in Immunology

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye L...

2022-02-21 21:00 1719

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai ...

2022-01-26 21:00 1505

Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai N...

2022-01-06 01:00 1994

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a glob...

2021-09-08 11:04 2054

Adlai Nortye Announces Formation of its New Scientific Advisory Board

HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceuti...

2021-03-08 09:00 1627

Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

NORTH BRUNSWICK, N.J., Aug. 24, 2020 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global c...

2020-08-24 13:13 1510